GVHD treatment costs in China: building an itemized RMB estimate

There is no single national price for treating graft-versus-host disease. Outpatient care for limited local symptoms, systemic treatment for chronic GVHD, and an admission for severe intestinal acute GVHD with infection or nutritional difficulties involve different resources. A patient who has already undergone transplantation may need complication management or a second opinion, so an advertised transplant package is not a reliable estimate for the current problem.

Key takeaways

These excerpts come from the original article. Read the full sections below for context.

Peking University People's Hospital lists expert consultations at RMB 1,000–4,000 per visit and inpatient ward charges at RMB 1,000–1,500 per day on its international-patient page. It states that additional examinations and treatment costs are discussed with the physician. These are published items for that service, not an all-inclusive GVHD admission price or a national tariff.[1]
Chronic eye or oral GVHD can require local medicines, specialist examination, and repeated review. Persistent dryness, corneal problems, oral pain, or swallowing difficulties may need care beyond the principal hematology prescription. EBMT guidance describes dedicated assessment of these complications; a systemic medicine does not automatically replace all local management.[8]
One estimate may contain only an expert consultation, while another includes admission and initial investigations. Their totals are not directly comparable. Match the ward category, medicine formulation and quantity, test frequency, supportive treatment, and follow-up arrangements. Where a third party charges for international coordination, identify the service provided, the recipient of payment, and how that charge relates to the hospital's own invoice.

Quick answer

Full guide

As of September 2026, some hospital consultation and ward charges can be verified publicly, but an individual, complete GVHD treatment quotation has not been obtained for this article. The distinction matters. A useful budget begins with the receiving team's clinical objective and an itemized estimate in RMB, rather than a fixed total chosen before the required treatment is known.

A verifiable hospital example covers only part of care

Peking University People's Hospital lists expert consultations at RMB 1,000–4,000 per visit and inpatient ward charges at RMB 1,000–1,500 per day on its international-patient page. It states that additional examinations and treatment costs are discussed with the physician. These are published items for that service, not an all-inclusive GVHD admission price or a national tariff.[1]

Confirm the applicable clinician, ward category, and current charge when arranging care. A ward figure cannot determine total admission cost without medicines, investigations, procedures, and support needs. Multiplying it by an unconfirmed number of days would produce false precision. It also should not be assumed to describe ordinary outpatient services or a different hospital's charging arrangements.

Define what the initial assessment needs to resolve

The first consultation may be intended to confirm GVHD, determine current activity, or explain symptoms recurring despite treatment. Intestinal acute GVHD assessment can require investigation for infection or other similar conditions. Chronic GVHD evaluation depends on the organ pattern and characteristic findings. Neither problem is best represented by automatically repeating an identical test package for every patient.[2,3]

Send previous pathology, laboratory trends, imaging, and treatment records in an organized form. Ask whether the center can review outside slides, original imaging files, and recent blood results. Complete documentation does not guarantee that no tests will be repeated, but it helps clinicians decide which information remains usable and which measurements must be updated. Missing specimen dates or incomplete reports can make that decision unnecessarily difficult.

Price the actual prescription rather than a box of medicine

A medication estimate should specify the generic name, formulation, strength, planned amount, and period covered. A GVHD regimen may include systemic treatment, local eye or oral medicines, infection prevention, and management of adverse effects. A lower box price does not necessarily produce a lower total regimen cost. Equally, a more expensive medicine should not be promised to save money overall merely because it might reduce another aspect of care.

Chinese ruxolitinib indications define relevant eligibility conditions, including age and prior-treatment response.[4] Chinese belumosudil prescribing information also addresses interactions that can affect its use and monitoring.[5] The pharmacy estimate therefore needs to follow the actual prescription. A coordinator should not calculate a personal monthly bill from a common dose found online before the treating clinician has made a decision.

Cellular treatment requires a product-specific quotation

China's conditional approval of amimestrocel injection concerns a defined group aged 14 years and older with steroid-treatment-failed acute GVHD predominantly involving the gastrointestinal tract. It does not authorize every mesenchymal stromal cell product for every form of GVHD.[6]

Ask which preparation is proposed, how many administrations are included in the near-term estimate, and whether preparation, infusion, observation, and required tests are charged separately. The plan should also explain how adverse events would be managed. A line reading only “stem cell treatment” is insufficient to connect the quotation to a specific product's evidence and indication.

Where no reliable Chinese price is publicly available, the correct budget entry remains a request for a hospital quotation. Converting a foreign product price into RMB would not establish what a Chinese center can legally provide or what the patient would actually pay there.

Intestinal disease can make supportive care a major component

Frequent diarrhea, poor absorption, or an inability to eat can make fluid, electrolyte, nutritional, and infection management important parts of treatment. Nutritional support depends on gastrointestinal function; intravenous nutrition is not universally preferable to oral or enteral support.[7] A budget containing only the main GVHD medicine may therefore omit clinically necessary care.

If endoscopy or biopsy is proposed, ask whether the procedure, sedation or anesthesia, pathology, and additional pathogen tests are separate items. The clinician should explain the question the investigation is intended to answer. Budget clarification helps a family understand charges, but it should not become an instruction to postpone essential assessment during serious illness. The estimate needs room to reflect the clinical findings rather than forcing them into a predetermined package.

Eye, oral, and lung involvement may create recurring costs

Chronic eye or oral GVHD can require local medicines, specialist examination, and repeated review. Persistent dryness, corneal problems, oral pain, or swallowing difficulties may need care beyond the principal hematology prescription. EBMT guidance describes dedicated assessment of these complications; a systemic medicine does not automatically replace all local management.[8]

Pulmonary chronic GVHD with bronchiolitis obliterans syndrome may require lung-function testing, respiratory input, and rehabilitation. The adult ERS/EBMT recommendations emphasize assessment and follow-up adapted to the situation.[9] Distinguish the first diagnostic evaluation from repeated monitoring. One spirometry price cannot represent the entire respiratory-care budget, but neither should a quotation assume that identical imaging is required at every visit without a clinical reason.

Photopheresis combines procedure costs with repeated attendance

Extracorporeal photopheresis usually involves more than one visit, and its schedule is adjusted according to response. Potential cost components include the procedure, vascular access, disposables, and associated testing; the providing hospital must confirm what its quoted price includes.[10] A session price becomes useful only when linked to a provisional schedule and reassessment point. It cannot guarantee that a specified number of visits will allow all medicines to stop.

For international patients, the attendance pattern also affects accommodation, local transport, and caregiver expenses. If treatment is to begin in China and continue at home, confirm whether a receiving center can provide the next phase and whether another assessment will be required. A low single-session charge may offer little practical advantage if continuity would require frequent international journeys.

Separate reimbursement information from the self-pay price

A medicine's appearance in a Chinese reimbursement document does not establish that every visitor qualifies for the same benefits. For example, a publicly available Sichuan attachment lists belumosudil with its payment scope and agreement period, but does not provide a public numerical figure that can be used as an individual self-pay quotation.[11] A symbol in a payment-standard column should not be interpreted as zero cost.

Patients enrolled in Chinese basic medical insurance should verify their actual settlement conditions through the hospital and the relevant insurance administration. International commercial insurance requires its own confirmation, including coverage for pre-existing disease, transplant complications, long-term outpatient medication, and research-related care. Direct billing, prior authorization, and final reimbursement are separate matters.

Obtain written confirmation from the insurer where possible. A statement that a hospital “works with insurance” does not establish that this patient's condition and proposed services are covered. The budget should show the expected patient contribution and identify any amount still awaiting approval rather than silently assuming full payment by an insurer.

A clinical trial is not necessarily a zero-cost pathway

A study may supply its investigational medicine while leaving some routine tests, admissions, or transport costs to the participant. Responsibilities should be explained by the study center in its consent and financial documentation. A registry entry can identify the study design and contact route, but a registration number alone does not establish an available place or that all care is free.[12]

Ask what happens financially if screening is unsuccessful, the participant withdraws, treatment stops because of toxicity, or the study ends. Before committing to accommodation, clarify which assessments require attendance and which records can be reviewed in advance. Participation should be planned alongside a route for standard care, so that a failed screening assessment does not leave the patient without treatment continuity.

Request estimates for three reviewable phases

The first estimate can cover diagnostic review and current organ assessment. The second can cover the clinician's proposed near-term treatment and monitoring. The third can describe expected prescriptions and follow-up once the condition is stable. Each should state its assumptions, inclusions, exclusions, and items that remain dependent on clinical review. These are budgeting phases, not a fixed medical schedule.

Chronic GVHD may require prolonged systemic treatment, but a median duration from a stopping-treatment cohort cannot supply an individual's billing period.[13] Estimating the funds needed until the next meaningful reassessment, then updating the plan, is more defensible than multiplying a drug price by an average number of months. It also makes it easier to explain a change in costs when a new treatment or complication changes the course.

Compare quotations only after matching their contents

One estimate may contain only an expert consultation, while another includes admission and initial investigations. Their totals are not directly comparable. Match the ward category, medicine formulation and quantity, test frequency, supportive treatment, and follow-up arrangements. Where a third party charges for international coordination, identify the service provided, the recipient of payment, and how that charge relates to the hospital's own invoice.

Other practical questions include whether a deposit is an advance against the eventual bill, how unused funds are reconciled, and whether an updated estimate will be provided when the clinical plan changes. These are matters to clarify with the center; the answers should not be assumed to be identical across institutions.

The useful outcome is an explainable RMB budget with stated uncertainties. In GVHD, the main unknowns are often the treatment required, the timing of reassessment, and whether additional medical needs arise. Making those conditions visible allows a family to plan and understand changes without mistaking a partial public charge for the cost of complete care.

References

Peking University People's Hospital. International patient FAQ and published charges: https://english.pkuph.cn/care/overview_g7yU_57.html
EBMT Handbook. Acute GVHD assessment and management: https://www.ncbi.nlm.nih.gov/books/NBK608233/
NIH. Chronic GVHD diagnosis and staging: https://pmc.ncbi.nlm.nih.gov/articles/PMC4329079/
Novartis China. Chinese ruxolitinib chronic GVHD indication: https://www.novartis.com.cn/news/jiekewei-linsuanluketinipianzhiliaomanxingyizhiwukangsuzhubingxinshiyingzhengzaihuahuopi
Sanofi China. Belumosudil prescribing information: https://www.sanofi.cn/assets/dot-cn/pages/docs/products/prescription-products/rezurock-cn-20260122.pdf
NMPA. Amimestrocel injection approval information: https://english.nmpa.gov.cn/2025-06/11/c_1101502.htm
EBMT Handbook. Nutritional support: https://www.ncbi.nlm.nih.gov/books/NBK608249/
EBMT Handbook. Ocular and oral complications: https://www.ncbi.nlm.nih.gov/books/NBK608294/
ERS/EBMT. Adult pulmonary chronic GVHD-related BOS recommendations, 2024: https://publications.ersnet.org/lookup/pmid/38485149
MSK. Photopheresis information: https://www.mskcc.org/cancer-care/patient-education/frequently-asked-questions-about-photopheresis
Sichuan Healthcare Security Administration. Separate-payment medicine attachment, including 2025–2026 agreements: https://ylbzj.sc.gov.cn/scsybj/nc010104/2024/12/27/1f686817d5c34811bb535e1be0b2c1fd/files/3%EF%BC%9A%E5%8D%95%E8%A1%8C%E6%94%AF%E4%BB%98%E7%AE%A1%E7%90%86%E7%9A%84%E8%8D%AF%E5%93%81%E5%90%8D%E5%8D%95.pdf
ClinicalTrials.gov. Example chronic GVHD study design, NCT06585774: https://clinicaltrials.gov/study/NCT06585774
Chen and colleagues. Durable systemic-treatment discontinuation in chronic GVHD: https://haematologica.org/article/view/haematol.2021.279814